| 詳細情報 |  |
|---|---|
| 関連リンク |  |
| 探す |  |
論文 (15件)
- Koki Matsushita, Yu Nagayoshi, Ryuichi Yoshii, Tomohumi Nakamura, Kengo Kajiwara, Yutaka Kakizoe, Yuichiro Izumi, Masataka Adachi, Masao Tomita, Yukimasa Kohda, et al. Rituximab as an Effective Treatment for New-onset Evans Syndrome and Systemic Lupus Erythematosus with Lupus Nephritis. Internal medicine (Tokyo, Japan). 2025
- Ryosuke Yamamura, Yu Nagayoshi, Kayo Nishiguchi, Hitomi Kaneko, Keiichi Yamamoto, Koki Matsushita, Miho Shimamura, Akihiro Kunisawa, Korin Sakakida, Takeshi Chujo, et al. Bacteria-specific modified nucleoside is released and elevated in urine of patients with bacterial infections. mBio. 2025
- Roland Tresky, Yuta Miyamoto, Yu Nagayoshi, Yasushi Yabuki, Kimi Araki, Yukie Takahashi, Yoshihiro Komohara, Huicong Ge, Kayo Nishiguchi, Takaichi Fukuda, et al. TRMT10A dysfunction perturbs codon translation of initiator methionine and glutamine and impairs brain functions in mice. Nucleic Acids Research. 2024
- Yasunobu Iwata, Qinyuan Deng, Yutaka Kakizoe, Terumasa Nakagawa, Yoshikazu Miyasato, Miyuki Nakagawa, Kayo Nishiguchi, Yu Nagayoshi, Yuki Narita, Yuichiro Izumi, et al. A Serine Protease Inhibitor, Camostat Mesilate, Suppresses Urinary Plasmin Activity and Alleviates Hypertension and Podocyte Injury in Dahl Salt-Sensitive Rats. International journal of molecular sciences. 2023. 24. 21
- 永田 裕子, 永芳 友, 柿添 豊, 安達 政隆, 仲里 仁史, 向山 政志, 富澤 一仁. 腎臓におけるtRNA修飾酵素CDKAL1の生理機能および足細胞機能との関連. 日本腎臓学会誌. 2023. 65. 3. 304-304
- 山村 遼介, 永芳 友, 柿添 豊, 安達 政隆, 富澤 一仁, 向山 政志. 腎不全に伴う血中修飾ヌクレオシド上昇から紐解く新規心腎連関分子メカニズムの解明. 日本腎臓学会誌. 2023. 65. 3. 305-305
- 西口 栞世, 永芳 友, 山村 遼介, 柿添 豊, 安達 政隆, 富澤 一仁, 向山 政志. 細菌特異的修飾ヌクレオシドの排泄メカニズムと生理学的意義. 日本腎臓学会誌. 2023. 65. 3. 325-325
- 永芳 友, 山村 遼介, 安達 政隆, 柿添 豊, 向山 政志. 修飾ヌクレオシドが織りなす新たな生体制御と腎不全に伴う血中濃度上昇から紐解く新規心腎連関分子メカニズムの解明. 日本内科学会雑誌. 2023. 112. 臨増. 153-153
- Yutaka Kakizoe, Terumasa Nakagawa, Yasunobu Iwata, Qinyuan Deng, Masataka Adachi, Yoshikazu Miyasato, Miyuki Nakagawa, Yu Nagayoshi, Kayo Nishiguchi, Yuki Narita, et al. Camostat mesilate, a serine protease inhibitor, exerts aquaretic effects and decreases urinary exosomal AQP2 levels. Journal of Pharmacological Sciences. 2022. 150. 4. 204-210
- Qinyuan Deng, Yutaka Kakizoe, Yasunobu Iwata, Terumasa Nakagawa, Yoshikazu Miyasato, Miyuki Nakagawa, Kayo Nishiguchi, Yu Nagayoshi, Masataka Adachi, Yuki Narita, et al. The serine protease plasmin plays detrimental roles in epithelial sodium channel activation and podocyte injury in Dahl salt-sensitive rats. Hypertension Research. 2022. 46. 1. 50-62
- Yu Nagayoshi, Kayo Nishiguchi, Ryosuke Yamamura, Takeshi Chujo, Hiroyuki Oshiumi, Hiroko Nagata, Hitomi Kaneko, Keiichi Yamamoto, Hirotomo Nakata, Korin Sakakida, et al. t6A and ms2t6A Modified Nucleosides in Serum and Urine as Strong Candidate Biomarkers of COVID-19 Infection and Severity. Biomolecules. 2022. 12. 9. 1233-1233
- 松永 愛子, 中村 敬志, 井上 秀樹, 嶋崎 明子, 永芳 友, 冨永 亜希, 三浦 玲, 中川 輝政, 柿添 豊, こう 健博, et al. 血漿交換を行うも救命しえず剖検に至った血栓性血小板減少性紫斑病の1例. 日本透析医学会雑誌. 2022. 55. 1. 41-47
- Y. Nagayoshi, T. Chujo, S. Hirata, H. Nakatsuka, C.-W. Chen, M. Takakura, K. Miyauchi, Y. Ikeuchi, B. C. Carlyle, R. R. Kitchen, et al. Loss of Ftsj1 perturbs codon-specific translation efficiency in the brain and is associated with X-linked intellectual disability. Science Advances. 2021. 7. 13. eabf3072-eabf3072
- Daisuke Fujimoto, Masataka Adachi, Yoshikazu Miyasato, Yusuke Hata, Hideki Inoue, Akira Oda, Yutaka Kakizoe, Terumasa Nakagawa, Akiko Shimasaki, Keishi Nakamura, et al. Efficacy of continuous erythropoietin receptor activator for end-stage renal disease patients with renal anemia before and after peritoneal dialysis initiation. Clinical and Experimental Nephrology. 2021. 25. 2. 191-199
- Yuichiro Izumi, Ami Hamaguchi, Rei Miura, Terumasa Nakagawa, Miyuki Nakagawa, Ken Saida, Noriko Miyake, Yu Nagayoshi, Yutaka Kakizoe, Taku Miyoshi, et al. Autosomal dominant Alport syndrome due to a COL4A4 mutation with an additional ESPN variant detected by whole-exome analysis. CEN case reports. 2020. 9. 1. 59-64
1〜15 件目 / 全 15 件
- « 最初
- ‹ 前へ
- 1
- 次へ ›
- 最後 »
